Products with Anti-platelet aggregation bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN6159 | Rubiarbonol B |
| 1. Rubiarbonol B may have antiplatelet aggregation activities. | |
| BCN6175 | Chrysophanol 8-O-glucoside |
| Chrysophanol-8-O-beta-D-glucopyranoside and chrysophanol have mild cytotoxicity and anti-diabetic properties and can play metabolic roles in the insulin-stimulated glucose transport pathway; it has potent inhibitory effect on collagen- and thrombin-induced platelet aggregation, it only inhibits platelet phosphatidylserine exposure.Chrysophanol-8-O-beta-D-glucopyranoside also exhibits significant anti-HBV activities with improved liver function, and enhanced HBeAg and HBsAg sero-conversion rates as well as HBV DNA clearance rates in HepG2 2.2.15 cells, DHBV models, or patients with chronic hepatitis B (CHB). | |
| BCN6197 | Pomolic acid |
| Pomolic acid has anti-cancer, anti-inflammatory and apoptotic activities, it can induce apoptosis in SK-OV-3 cells, which is mediated by the mitochondrial-mediated intrinsic and death receptor-induced extrinsic pathways. Pomolic acid is a potent inhibitor of the aggregation of human platelets induced by ADP and Epinephrine, exhibits IC50 values close to 60 nM and 20 nM, respectively; pomolic acid does not inhibit human platelet aggregation induced by PAF, collagen, U46619 (thromboxane analogue), TRAP or arachidonic acid; suggests that the hypotensive and platelet anti-aggregating effects of pomolic acid and its potential role in cardiovascular therapy. | |
| BCN6250 | Hispidulin |
| Hispidulin has anti-oxidative, anti-inflammatory, anti-cancer, antiepileptic, neuroprotective, anti-osteoporotic and bone resorption attenuating effects, it targets the VEGF receptor 2-mediated PI3K/Akt/mTOR signaling pathway in endothelial cells, leading to the suppression of pancreatic tumor growth and angiogenesis. Hispidulin can ameliorate high glucose-mediated endothelial dysfunction via inhibiting PKCβII-associated NLRP3 inflammasome activation and NF-κB signaling, it has potential application in the prevention and treatment of diabetic vascular complications. Hispidulin can inhibit platelet aggregation by elevating cAMP levels by a mechanism different from that of theophylline or PGE1. | |
| BCN6289 | Anemarsaponin B |
| Anemarsaponin B can inhibit PAF-induced rabbit platelet aggregation in vitro. Anemarsaponin B has anti-inflammatory effect in LPS-treated RAW 264.7macrophages, the effect is associated with the inhibition of NF-κB transcriptional activity, possibly via the p38 MAP kinase pathway. | |
